drugset / Trial / NCT02207920

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

NCT02207920

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.

Timeline

Start
2014-07
Primary completion
2015-12
Completion
2015-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AIDSVAX B/E Vaccine 600 ug/ml Intramuscular
Subject DNA-HIV-PT123 Vaccine 4 mg/ml Intramuscular